Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2007
10/17/2007CN101053403A Anti-senility anti-fatigue body-beautifying food and preparation method thereof
10/17/2007CN101053375A Eggs with non-pollution and building up body functions
10/17/2007CN100343393C Central airway administration for systemic delivery of therapeutics
10/17/2007CN100343282C Hybrid interferon compositions and methods of use
10/17/2007CN100343280C CUDR as biomarker for cancer progression and therapeutic response
10/17/2007CN100343273C C17-hydroxy-steroid lactone antitumour medicine
10/17/2007CN100343272C Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates
10/17/2007CN100343271C C27-steroid antitumour medicine
10/17/2007CN100343270C Process for extracting anticancer product from natural plant
10/17/2007CN100343268C Beta -2'-or 3'-halonucleosides
10/17/2007CN100343258C Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines
10/17/2007CN100343254C Pyrrolopyrimidine derivatives
10/17/2007CN100343238C Quinazoline derivatives as antitumor agents
10/17/2007CN100343237C Amide derivative and medicine
10/17/2007CN100343235C Nucleophile substituted ecteinascidins and N-oxide ecteinsacidins
10/17/2007CN100343216C Synthesis of Combretastatin A-4 supported by polymer
10/17/2007CN100342914C Taxadol slow release nano-particle, its preparation method and application
10/17/2007CN100342908C Pharmaceutical form of administration for peptides, method for its production and use
10/17/2007CN100342906C Use of polyproline polypeptide in preparing medicine for treating malignant tumour
10/17/2007CN100342853C Therapeutic treatment
10/16/2007USRE39887 A cyclic depsipeptide from a tunicate of the Ascidiacea class; viricides, antitumor agents, immunosuppressants and cytotoxic agents
10/16/2007US7282608 Inhibitors of histone deacetylase
10/16/2007US7282595 Therapy of adenocarcinoma of the colon and rectum
10/16/2007US7282591 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
10/16/2007US7282585 Salt and crystalline forms of (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
10/16/2007US7282518 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
10/16/2007US7282504 Kinase inhibitors
10/16/2007US7282500 Nitrogen compounds such as 4-(1-Hydroxyimino-indan-5-yl)-5-pyridin-4-yl-1H-imidazole-2-carboxylic Acid (2-morpholin-4-yl-ethyl)-amide, used as anticarcinogenic agents and for prophylaxis of brain disorders
10/16/2007US7282490 Osteopontin-related compositions and methods
10/16/2007US7282481 Improved thermostability, acid resistance, alkali resistance, resistance to proteolytic enzymes, and DNA synthesis promoting activity
10/16/2007US7282476 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
10/16/2007US7282344 Also mutated GABAA receptor subunits, polynucleotide sequences encoding mutated subunits, expression vectors comprising the mutated subunits, host cells capable of expressing the mutated subunits, drug screening methods, and chemical substances identified by the method; high throughput drug screening
10/16/2007US7282222 Methods and compositions for directing cells to target organs
10/16/2007US7282216 Prepared by blending hydrophobic biocompatible, biodegradable polymers or copolymers, such as poly(lactide-co-glycolide), and a biocompatible, amphipathic copolymer having a water absorption ratio of 2 or less; sustained release drug delivery
10/16/2007US7282215 Supports for photosensitizer formulations
10/16/2007US7282204 modulating tumor growth by contacting a tumor cell with an agonist or antagonist of IL-23, particularly a binding mixture of IL-23R or nucleotide coding it comprising: an antigen-binding site of an antibody; an extracellular region of IL-23R; a small molecule; and an anti-sense nucleic acid or siRNA
10/16/2007CA2327253C Sulfonamide-containing indole compounds
10/16/2007CA2319275C Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
10/16/2007CA2281807C Method of treating a tumor
10/11/2007WO2007115269A2 Orally bioavailable caffeic acid related anticancer drugs
10/11/2007WO2007114851A1 Methods and compositions to induce cell death of invasive tumors
10/11/2007WO2007114697A1 Novel composition for tumor growth control
10/11/2007WO2007114496A1 Novel anti-cd98 antibody
10/11/2007WO2007114323A1 Aminopyrrolidine compound
10/11/2007WO2007114262A1 Casein nanoparticle
10/11/2007WO2007114239A1 ANTI-CANCER AGENT COMPRISING DGKα INHIBITOR
10/11/2007WO2007114213A1 Substituted bicyclic cyclic derivative and use thereof
10/11/2007WO2007114199A1 Process for producing optically active (s)-7-hydroxy-6-methylheptane-2-one and precursor thereof
10/11/2007WO2007114013A1 Composition containing lignan compound
10/11/2007WO2007113671A1 Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
10/11/2007WO2007113648A2 Ctla4 antibody combination therapy
10/11/2007WO2007113647A1 Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
10/11/2007WO2007113596A1 Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
10/11/2007WO2007113565A1 Naphthyridine derivatives as anti-cancer agents
10/11/2007WO2007113557A1 Substituted quinazolines with anti-cancer activity
10/11/2007WO2007113548A1 Naphthyridine derivatives
10/11/2007WO2007113386A1 Peptide conjugates
10/11/2007WO2007113385A1 Diagnostic and therapeutic agents
10/11/2007WO2007113269A2 15-desmethoxymacbecin derivatives for the treatment of cancer diseases
10/11/2007WO2007113249A2 N-hydroxy-3-(4-{3-phenyl-s-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer
10/11/2007WO2007113246A1 Thiazolyldihydroindazole derivatives as protein kinase inhibitors
10/11/2007WO2007113245A1 Thiazolyl dihydro-indazoles
10/11/2007WO2007113212A2 Use of a kinase inhibitor for the treatment of particular resistant tumors
10/11/2007WO2007113198A2 Use of a kinase inhibitor for the treatment of particular resistant tumors
10/11/2007WO2007113005A2 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
10/11/2007WO2007113000A1 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS
10/11/2007WO2007112648A1 The medicinal compositions comprising triptolide derivatives and its dosage form and application
10/11/2007WO2007112567A1 Synthetic archaeal glycolipid adjuvants
10/11/2007WO2007112531A1 Use of protease inhibitors from bauhinia bauhinioides and/or enterolobium contortisiliquum
10/11/2007WO2007112475A1 A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
10/11/2007WO2007094495A3 Novel anticancer cathepsin preparation and anticancer agent for combination therapy against cancer using the same
10/11/2007WO2007092213A3 Inhibitors of e1 activating enzyme
10/11/2007WO2007085470A3 Cd19-specific immunotoxin and treatment method
10/11/2007WO2007085412B1 Fgf2-binding peptides and uses thereof
10/11/2007WO2007071409A8 Method for treating colon cancer
10/11/2007WO2007042465A3 Combinati0n of nilotinib with farnesyl transferase inhibitors
10/11/2007WO2007002720A3 An impurity of anastrozole intermediate, and uses thereof
10/11/2007WO2006108948A3 Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein hsp90 activities
10/11/2007WO2006064277A8 Silicon compounds and their use
10/11/2007WO2000072801A3 Alpha v integrin receptor antagonists
10/11/2007US20070238875 Heterocyclic compounds
10/11/2007US20070238862 natural ligand for the orphan G-Protein Coupled Receptor (GPCR) ChemerinR and uses thereof in diagnosis and immuno therapy of a disease; monoclonal antibody; chemiattractant proteins; useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of GPCR signaling
10/11/2007US20070238791 Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators
10/11/2007US20070238781 Compounds for the modulation of the glykolysis-enzyme-and/or of the transaminase-complex
10/11/2007US20070238776 Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine
10/11/2007US20070238769 Bone Densifying Agent Characterized By Use Of Cathepsin K Inhibitor With Pth
10/11/2007US20070238763 Urea derivatives as integrin a4 antagonists
10/11/2007US20070238759 Novel Polymorph V of Torasemide
10/11/2007US20070238741 Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine
10/11/2007US20070238736 4-(1-Piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 4-[4-(Benzo [1,3]dioxole-5-carbonyl)-piperazin-1-yl]-1-(4-fluoro-benzyl)-2-oxo-1,2-dihydro-quinoline-3-carbonitrile; antitumor and angiogenesis inhibitor, antiinflammatory, antidiabetic agent, autoimmune disorder
10/11/2007US20070238735 Cyclooxygenase-2 selective inhibitors, compositions and methods of use
10/11/2007US20070238734 Jnk inhibitors
10/11/2007US20070238729 Dna-pk inhibitors
10/11/2007US20070238714 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
10/11/2007US20070238686 Inhibition of Chronic Myelogenous Leukemic Cell Growth By Liposomal-Antisense Oligodeoxy-Nucleotides Targeting To Grb2 or Crk1
10/11/2007US20070238677 Pharmaceutical Composition Containing Hshrd3
10/11/2007US20070238659 Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
10/11/2007US20070238178 Cancer vaccines; infections from Retrovirus, Herpesvirus, Hepadenovirus, Poxvirus, Parvovirus, Papillomavirus, or Papovavirus; reduced side effects; a hairpin RNA having a double stranded region of between 11 to 30 nucleotides; gene expression inhibition
10/11/2007US20070237848 MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
10/11/2007US20070237771 Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
1 ... 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 ... 2211